Literature DB >> 6445792

Epidemiological information on leprosy in the Singu area of Upper Burma.

V Martínez Domínguez, P Gallego Garbajosa, M Mg Gyi, C T Tamondong, T Sundaresan, L M Bechelli, K Lwin, H Sansarricq, J Walter, F M Noussitou.   

Abstract

In the course of a WHO trial designed to evaluate the possible protective action of BCG vaccine against leprosy, a longitudinal epidemiological study of the whole population was carried out in an area of very high endemicity in Burma from 1964 to 1976. Two mass surveys of the whole population with an interval of 4 years and annual re-examination of the 28 000 children (0-14 years) in the BCG trial were carried out. The data collected yielded important information about general prevalence and yearly incidence of the disease as well as on sex, age, and classification of cases. The general prevalence rate declined from 32.6 per 1000 in the first survey to 25.2 per 1000 in the second. The number of cases among males was significantly higher than among females. Incidence rate among contacts of already known cases was 9.8 per 1000 person-years. The estimated yearly incidence among non-contacts was 5.9 per 1000. Prevalence rates reached a peak in the 20-39-year age group. The prevalence rate of multibacillary patients also reached a peak in the same age bracket. It is stressed that a further period of epidemiological surveillance will be essential in order to have a correct estimate of the expected number of new infections, especially multibacillary cases, in the 20-39-year group. The value of this information is considered unique for planning and programming of future control activities.

Entities:  

Mesh:

Year:  1980        PMID: 6445792      PMCID: PMC2395894     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  5 in total

1.  BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma.

Authors:  L M Bechelli; P G Garbajosa; M M Gyi; K Uemura; T Sundaresan; V Martínez Domínguez; M Matejka; C Tamondong; R Quagliato; V Engler; M Altmann
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

2.  BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.

Authors:  L M Bechelli; K Lwin; P Gallego Garbajosa; K Uemura; T Sundaresan; C Tamondong; M Matejka; H Sansarricq; J Walter
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

3.  Epidemiology and leprosy control.

Authors:  T W Meade
Journal:  Lepr Rev       Date:  1971-03       Impact factor: 0.537

4.  BCG vaccination of children against leprosy. Preliminary findings of the WHO-controlled trial in Burma.

Authors:  L M Bechelli; G Garbajosa; K Uemura; V Engler; V Martínez Domínguez; L Paredes; T Sundaresan; G Koch; M Matejka
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

5.  Some epidemiological data on leprosy collected in a mass survey in Burma.

Authors:  L M Bechelli; P Gallego Garbajosa; M M Gyi; K Uemura; T Sundaresan; C Tamondong; V Martínez Domínguez; J Walter
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

  5 in total
  2 in total

Review 1.  Socioeconomic risk markers of leprosy in high-burden countries: A systematic review and meta-analysis.

Authors:  Julia Moreira Pescarini; Agostino Strina; Joilda Silva Nery; Lacita Menezes Skalinski; Kaio Vinicius Freitas de Andrade; Maria Lucia F Penna; Elizabeth B Brickley; Laura C Rodrigues; Mauricio Lima Barreto; Gerson Oliveira Penna
Journal:  PLoS Negl Trop Dis       Date:  2018-07-09

2.  Socioeconomic determinants of leprosy new case detection in the 100 Million Brazilian Cohort: a population-based linkage study.

Authors:  Joilda Silva Nery; Anna Ramond; Julia Moreira Pescarini; André Alves; Agostino Strina; Maria Yury Ichihara; Maria Lucia Fernandes Penna; Liam Smeeth; Laura C Rodrigues; Mauricio L Barreto; Elizabeth B Brickley; Gerson Oliveira Penna
Journal:  Lancet Glob Health       Date:  2019-07-19       Impact factor: 26.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.